A promising molecule, called BT13, has offered hope for a new treatment that could stop or slow Parkinson’s, something no treatment can currently do.
Researchers from the University of Helsinki have found that molecule BT13 has the potential to both boost levels of dopamine, the chemical that is lost in Parkinson’s, as well as protecting the dopamine-producing brain cells from dying.
The results from the study, co-funded by Parkinson’s UK, showed an increase in dopamine levels in the brains of mice following treatment with the molecule. BT13 also activated a specific receptor in the mouse brains to protect the cells.
These findings suggest that BT13 could have the potential to lead to a new drug treatment that can slow, stop or even reverse the loss of brain cells in Parkinson’s.
Why is dopamine important?
Typically, by the time people are diagnosed with Parkinson’s, they have already lost 70-80 per cent of their dopamine-producing cells. These are involved in coordinating movement.
Current treatments mask the symptoms, but there is nothing that can slow down its progression or prevent more brain cells from being lost. As dopamine levels continue to fall, symptoms get worse and new symptoms can appear.
The role of BT13
Researchers are now working on improving the properties of BT13 to make it more effective as a potential treatment. If successful, this could benefit the 145,000 people living with Parkinson’s in the UK.
The study builds on previous research on another molecule that targets the same receptors in the brain, glial cell line-derived neurotrophic factor (GDNF), an experimental treatment for Parkinson’s which was the subject of a major clinical trial funded by Parkinson’s UK. While the results were not clear cut, GDNF has shown promise to restore damaged cells in Parkinson’s.
The GDNF protein requires complex surgery to deliver the treatment to the brain because it’s a large molecule. However BT13, a smaller molecule, could be more easily administered as a treatment if shown to be beneficial in further clinical trials.
“The molecule holds great promise”
Professor David Dexter, Deputy Director of Research at Parkinson’s UK, said: “People with Parkinson’s desperately need a new treatment that can stop the condition in its tracks, instead of just masking the symptoms.
“One of the biggest challenges for Parkinson’s research is how to get drugs past the blood-brain barrier, so the exciting discovery of BT13 has opened up a new avenue for research to explore.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Coronavirus: Parkinson's sufferer asked to leave Wellington cafe after coughingon March 21, 2020 at 10:16 pm
A man with Parkinson's who was asked to leave a Wellington cafe after coughing now feels uncomfortable leaving his home. Luke Harrison said his father, in his late 60s, was at Wellington cafe Smith ...
- Brain-stimulating implant can turn down Parkinson’s symptoms as requiredon March 19, 2020 at 1:16 pm
Special brain implants could help “turn down” the effects of Parkinson’s disease, research shows. The treatment is a variation on conventional deep brain stimulation treatment, which is already used ...
- Parkinson's Disease Treatment Market 2020 Demand, Current Trends, Growth Analysis, Competitor Analysis, Future Forecast 2025on March 19, 2020 at 4:28 am
New York, March 19, 2020: The Parkinson's Disease Treatment Market is segmented on the lines of its drug class, distribution channel, patient care setting and regional. Based on drug class it covers ...
- Brain implant detects and turns down symptoms of Parkinson’s diseaseon March 18, 2020 at 11:10 am
People with Parkinson’s disease are getting brain implants that can automatically detect and reduce harmful nerve cell activity, to test if the technique could reduce movement difficulties. The device ...
- Swiss bio Addex halts Parkinson's test as trial delays tick up on COVID-19 disruptionon March 18, 2020 at 4:25 am
Addex Therapeutics has seen its shares down 15% on the news that it has had to delay a registrational study of its Parkinson’s disease candidate. The trial, known as study 301, was of dipraglurant to ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Bt45 shaved off price of cooking gason March 19, 2020 at 9:39 pm
Please call: Mr.Chalengpot Boonsue - Vice President +662 338 3155 ...
- Friday the 13th: Thai bourse uses “circuit breaker” as coronavirus batters Thai stockson March 13, 2020 at 2:03 am
“Foreign investors made net sales of Bt1.929 billion in the stock market and Bt13.646 billion in the bond market, while there are 28,243 net long TFEX contracts.” The analyst says he expects the SET ...
- SET uses circuit breaker as Covid-19 worries pummel Thai stockson March 12, 2020 at 10:58 pm
“Foreign investors made net sales of Bt1.929 billion in the stock market and Bt13.646 billion in the bond market, while there are 28,243 net long TFEX contracts.” The analyst expected the SET Index to ...
- Thai Airways 2019 losses widen despite increased trafficon March 1, 2020 at 11:35 pm
As at 31 December 2019, cash and cash equivalents amounted to Bt21.7 billion, up from Bt13.7 billion one year before. The airline’s fleet remained unchanged at 103 aircraft, including the 20 ...
- Research Roundup: Misfolding DNA and Type 1 Diabetes and Moreon February 21, 2020 at 11:46 am
They believe it would lead to early diagnosis. Potential Treatment for Parkinson’s Disease Researchers at the University of Helsinki have identified a molecule called BT13 that potentially can ...